The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
 
Tanya Jindal
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose
 
Cindy Jiang
No Relationships to Disclose
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Exelixis; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AVEO; Exelixis; Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen
 
Omar Alhalabi
Consulting or Advisory Role - Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Ikena Oncology (Inst)
 
Amanda Nizam
Consulting or Advisory Role - AVEO
 
Arnab Basu
Honoraria - Cardinal Health; Eisai; Gilead Sciences; Natera
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; EMD Serono; Seagen
Speakers' Bureau - Eisai
Research Funding - Astellas Pharma (Inst); AVEO (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Natera (Inst)
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb/Medarex; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; EMD Serono; Exelixis; Janssen; Myovant Sciences; Novartis; Pfizer; Roche/Genentech; Seagen; TTC Oncology
Research Funding - Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Newlink Genetics
 
Matthew I. Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Consulting or Advisory Role - Loxo/Lilly
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); G1 Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape
 
Sumit Shah
No Relationships to Disclose
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); Nektar (Inst); NeoImmuneTech (Inst); Novartis (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Nancy B. Davis
Consulting or Advisory Role - Janssen Biotech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst)
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar; Nektar
Honoraria - Bristol Myers Squibb Foundation
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Hamid Emamekhoo
Consulting or Advisory Role - Cardinal Health; Exelixis; Seagen; Seagen
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Joaquim Bellmunt
Stock and Other Ownership Interests - Rainier Therapeutics
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate Bladder Cancer
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer
 
Matthew T Campbell
Honoraria - AstraZeneca; Axdev; Curio Science; Exelixis; Medscape; Seagen; Targeted Oncology
Consulting or Advisory Role - EMD Serono; Exelixis; Pfizer; SeaGen
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; SeaGen
Other Relationship - Curio Science
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte (Inst); Merck (Inst); Nektar (Inst); Taiho Oncology (Inst)